Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Harvard Business School
McKesson
Johnson and Johnson
Medtronic

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,008,923

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,008,923 protect, and when does it expire?

Patent 7,008,923 protects VIBATIV and is included in one NDA.

This patent has ninety-three patent family members in thirty-four countries.

Summary for Patent: 7,008,923
Title:Glycopeptide phosphonate derivatives
Abstract:Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s): Leadbetter; Michael R. (San Leandro, CA), Linsell; Martin S. (San Mateo, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:11/037,934
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition; Process;

Drugs Protected by US Patent 7,008,923

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-001 Sep 11, 2009 DISCN Yes No   Start Trial   Start Trial METHOD OF TREATING A STAPHYLOCOCCAL INFECTION   Start Trial
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes   Start Trial   Start Trial METHOD OF TREATING A STAPHYLOCOCCAL INFECTION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,008,923

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 035333   Start Trial
Austria 337334   Start Trial
Austria 388960   Start Trial
Austria 402951   Start Trial
Austria 416791   Start Trial
Australia 2001261107   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Baxter
AstraZeneca
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.